APIM Therapeutics

Norway
Trondheim, Trøndelag, Norway, N-7491

Company profile

APIM Therapeutics company profile

APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellular responses to DNA damage and stress.

Business identity

Contact email
[email protected]
Phone number
+47 73 49 4002
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2009-01-01

Headquarters

Postal code
N-7491
Country code
NO
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
3
Total equity funding
$3M
Last funding
Series Unknown / $3M / 2017-12-08
Last equity funding
Series Unknown / $3M
Investors
4
Lead investors
1
Founders
1
Articles
5

Founders and investors

Founders

Marit Otterlei

Lead investors

TeleVenture Management

Investors

Birk VentureInvestinorSarsia Seed ManagementTeleVenture Management